Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Metastatic Pancreatic Adenocarcinoma 1Lymphoma, T-Cell 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Gemcitabine 5Irinotecan 2Albumin-Bound Paclitaxel 2regorafenib 1pembrolizumab 1olaparib 1ibrutinib 1Tetrahydrouridine 1Telemedicine 1Taxes 1Practice Guidelines as Topic 1Paclitaxel 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Erlotinib Hydrochloride 1Docetaxel 1Decitabine 1Counseling 1Cisplatin 1Capecitabine 1BKT140 14-fluorobenzoyl-TN-14003 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Pancreatic Adenocarcinoma × Tetrahydrouridine × Clear all
NCT02847000 2019-01-09

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
13 enrolled
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡